We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$316M
Cap. Flow
-$376M
Cap. Flow %
-51.38%
Top 10 Hldgs %
46.9%
Holding
119
New
21
Increased
21
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$26M
2
INSM icon
Insmed
INSM
+$25.6M
3
TRVI icon
Trevi Therapeutics
TRVI
+$7.99M
4
ELVN icon
Enliven Therapeutics
ELVN
+$7.57M
5
VTYX
Ventyx Biosciences
VTYX
+$7.33M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$17.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$16.8M
3
MRUS
Merus
MRUS
+$11.8M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$8.19M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$7.44M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$57.7M 7.88%
610,000
-5,000
-0.8% -$370K
INSM icon
2
Insmed
INSM
$23.5B
$47.8M 6.53%
475,000
+335,000
+239% +$25.6M
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.6B
$34.4M 4.7%
1,100,000
-228,175
-17% -$7.44M
ACLX
4
DELISTED
Arcellx
ACLX
$32.6M 4.45%
495,000
-35,000
-7% -$2.18M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$32M 4.38%
+250,000
New +$26M
NUVL
6
DELISTED
Nuvalent
NUVL
$31.7M 4.32%
415,000
-45,000
-10% -$3.29M
APGE icon
7
Apogee Therapeutics
APGE
$10.1B
$30M 4.1%
691,899
-459,300
-40% -$17.5M
ALKS icon
8
Alkermes
ALKS
$8.79B
$28.6M 3.91%
1,000,000
– –
PTGX icon
9
Protagonist Therapeutics
PTGX
$9.06B
$24.3M 3.32%
440,000
+40,000
+10% +$1.92M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.8B
$24.2M 3.31%
80,000
– –
TEVA icon
11
Teva Pharmaceuticals
TEVA
$37.3B
$23.5M 3.2%
1,400,000
– –
EXEL icon
12
PUT
Exelixis
EXEL
$14.1B
$19.8M 2.71%
+450,000
New +$18M
LXEO icon
13
Lexeo Therapeutics
LXEO
$368M
$14.4M 1.97%
3,589,355
+2,108,474
+142% +$6.93M
TVTX icon
14
Travere Therapeutics
TVTX
$5.27B
$14.4M 1.96%
970,000
-100,000
-9% -$1.66M
ESTA icon
15
Establishment Labs
ESTA
$2.72B
$14.3M 1.95%
334,863
+54,863
+20% +$1.91M
TRVI icon
16
Trevi Therapeutics
TRVI
$2.71B
$13.9M 1.89%
2,534,058
+1,284,058
+103% +$7.99M
WVE icon
17
Wave Life Sciences
WVE
$1.12B
$13M 1.78%
2,000,308
+175,308
+10% +$1.16M
VERA icon
18
Vera Therapeutics
VERA
$2.76B
$12.8M 1.75%
545,000
+189,857
+53% +$4.27M
MLYS icon
19
Mineralys Therapeutics
MLYS
$2.39B
$12.2M 1.66%
900,000
-200,000
-18% -$2.9M
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$11.8M 1.62%
900,162
-646,500
-42% -$8.19M
AMGN icon
21
CALL
Amgen
AMGN
$198B
$11.2M 1.53%
40,000
-30,000
-43% -$8.5M
NRIX icon
22
Nurix Therapeutics
NRIX
$2.4B
$11M 1.51%
967,620
+156,951
+19% +$1.7M
RZLT icon
23
Rezolute
RZLT
$444M
$9.81M 1.34%
2,200,000
+500,000
+29% +$1.86M
CRSP icon
24
CALL
CRISPR Therapeutics
CRSP
$4.71B
$9.73M 1.33%
+200,000
New +$7.74M
VTYX
25
DELISTED
Ventyx Biosciences
VTYX
$9.71M 1.33%
+4,536,182
New +$7.33M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Affinity Asset Advisors held 119 positions worth $732M, down 30% from $1.05B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $376M in Q2 2025, closing 28 positions and reducing 25 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 55% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Blueprint Medicines worth $32M.

  • Affinity Asset Advisors's largest Q2 2025 buy was Blueprint Medicines: 250,000 shares worth $32M.
  • Affinity Asset Advisors added most to Insmed in Q2 2025, an estimated $25.6M increase.
  • Affinity Asset Advisors's biggest Q2 2025 reduction was Apogee Therapeutics, cutting an estimated $17.5M.
  • Affinity Asset Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q2 2025, selling an estimated $16.8M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $732M portfolio in Q2 2025.
  • Affinity Asset Advisors opened 21 new positions and closed 28 in Q2 2025.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $732M.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.